论文部分内容阅读
目的:探讨吉西他滨联合卡铂治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将98例晚期NSCLC患者随机分入A组(吉西他滨联合卡铂)和B组(吉西他滨联合顺铂),A组给予吉西他滨1 000mg/m2,d1～d2,静脉滴入,卡铂根据曲线下面积=5给药,d1,静脉滴入;B组在吉西他滨给药的同时,给予顺铂80mg/m2,d1～d2,静脉滴入。21d为1个周期,至少治疗2个周期。比较两组治疗有效率、1年生存率、不良反应发生率及生活质量。结果:A组有效率(CR+PR)为39.7%(23/58),B组CR+PR 40.0%(16/40);A组与B组1年生存率分别为52.1%和45.0%,两组有效率及1年生存率均差异无统计学意义,P>0.05;A组无Ⅲ+Ⅳ度胃肠道反应,显著少于B组的12.5%,P<0.05;治疗后A组LCSS量表评分显著优于B组,P<0.05。结论:吉西他滨联合卡铂或顺铂治疗晚期NSCLC同等有效,但前者不良反应少,患者耐受性好,生活质量高。
Objective: To investigate the clinical efficacy of gemcitabine combined with carboplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Ninety-nine patients with advanced NSCLC were randomly divided into group A (gemcitabine plus carboplatin) and group B (gemcitabine plus cisplatin). Group A received Gemcitabine 1 000 mg / m2, d1 to d2 for intravenous infusion. According to the curve Under the area = 5 administration, d1, intravenous infusion; Group B while gemcitabine administered cisplatin 80mg / m2, d1 ~ d2, intravenous infusion. 21d for a period of at least two cycles of treatment. The treatment efficiency, 1-year survival rate, incidence of adverse reactions and quality of life were compared between the two groups. Results: The effective rate (CR + PR) in group A was 39.7% (23/58) and in group B CR + PR was 40.0% (16/40). The 1-year survival rates in group A and group B were 52.1% and 45.0% There was no significant difference between the two groups in the effective rate and the 1-year survival rate (P> 0.05). There was no Ⅲ + Ⅳ gastrointestinal reaction in group A, which was significantly less than that in group B (12.5%, P <0.05) Scale score was significantly better than the B group, P <0.05. Conclusions: Gemcitabine combined with carboplatin or cisplatin is equally effective in the treatment of advanced NSCLC. However, the former has fewer adverse reactions, good patient tolerance and high quality of life.